NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE269485 Query DataSets for GSE269485
Status Public on Aug 29, 2024
Title Transcriptomics-informed pharmacology identifies epigenetic and cell cycle regulators as enhancers of AAV production
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Recombinant adeno-associated virus (rAAV) is a widely used viral vector for gene therapy. Despite its clinical efficacy, the manufacturing of rAAV faces challenges in productivity and quality, leading to limited availability. To address the growing demand, next-generation process development should be informed by a mechanistic understanding of the cellular response to rAAV. In this study, we performed transcriptomic analysis of 5 cell lines with variable capacities for rAAV production. Using an intersectional approach, we assessed the transcriptional response to rAAV production and compared transcriptional profiles between high and baseline producers to identify possible targets for enhancing production. Modulation of cell cycle and nucleosome components suggested a reduction of proliferative capacity and a shift toward DNA replication to support rAAV production. During rAAV production, we observed upregulation of several core functions including transcription, stress response, and Golgi and endoplasmic reticulum organization. Conversely, inhibitors of DNA-binding proteins and mitochondrial components were consistently downregulated during rAAV production. We next performed a drug connectivity analysis of these results and identified 5 classes of drugs predicted to enhance rAAV production. Validation studies confirmed the efficacy of HDAC and microtubule inhibitors. Our data uncover novel and previously identified pathways that may enhance rAAV productivity, potentially enabling a path to engineer improved processes and cell lines for higher yields and better quality rAAV production.
 
Overall design Using a triple plasmid transfection, we produced rAAV in 5 different HEK293 cell lines. We collected total RNA for transcriptome analysis at 3 time points: before transfection (0 hr), 24 hours, and 72 hours after transfection.
We identified differentially expressed genes between time points to determine how AAV production affects gene expression. We also compared gene expression profiles between 2 high and 2 baseline AAV-producing cell lines to identify genes that are associated with enhanced AAV production.
Web link https://www.biorxiv.org/content/10.1101/2024.06.14.599118v1
 
Contributor(s) Tworig JM, Grafton F, Hörer M, Reid CA, Mandegar MA
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Jun 10, 2024
Last update date Aug 30, 2024
Contact name Joshua Tworig
Organization name Ascend Advanced Therapies
Street address 1010 Atlantic Ave., Suite 102
City Alameda
State/province CA
ZIP/Postal code 94501
Country USA
 
Platforms (1)
GPL34281 Illumina NovaSeq X (Homo sapiens)
Samples (45)
GSM8316355 AC1.230, 0hr, 1
GSM8316356 AC1.230, 0hr, 2
GSM8316357 AC1.230, 0hr, 3
Relations
BioProject PRJNA1122129

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE269485_RAW.tar 12.0 Mb (http)(custom) TAR (of CSV)
SRA Run SelectorHelp
Raw data are available in SRA

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap